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Abstract  21 
Context & Objective: The Controlled Antenatal Thyroid Screening (CATS) study 22 
investigated treatment for suboptimal gestational thyroid function (SGTF) on childhood 23 
cognition and found no difference in IQ at 3 years between children of treated and 24 
untreated SGTF mothers. We have measured IQ in the same children at age 9.5-years 25 
and included children from normal-GTF mothers.  26 
Design, Setting & Participants: One examiner, blinded to participant group, assessed 27 
children’s IQ (WISC-IV), long-term memory and motor function (NEPSY-II) from 28 
children of 119 treated and 98 untreated SGTF mothers plus children of 232 mothers 29 
with normal-GTF. Logistic regression explored the odds and percentages of IQ<85 in 30 
the groups.  31 
Results: There was no difference in IQ<85 between children of mothers with normal-32 
GTF and combined SGTF i.e. treated and untreated (fully adjusted OR=1.15 (95% CI 33 
0.52, 2.51) p=0.731). Furthermore, there was no significant effect of treatment 34 
(untreated OR=1.33 (95% CI 0.53, 3.34), treated OR=0.75 (95% CI 0.27, 2.06) 35 
p=0.576). IQ< 85 was 6.03% in normal-GTF, 7.56% in treated and 11.22% in untreated 36 
groups. Analyses accounting for treated-SGTF women with FT4 >97.5th centile of the 37 
entire CATS-I cohort revealed no significant effect on child’s IQ<85 in CATS-II. IQ at 38 
age 3 predicted IQ at age 9.5 (p<0.0001) and accounted for 45% of the variation. 39 
Conclusions: Maternal thyroxine during pregnancy did not improve child cognition at 40 
age 9.5 years. Our findings confirmed CATS-I and suggest that the lack of treatment 41 
effect may be due to the similar proportion of IQ<85 in children of women with normal-42 
GTF and SGTF. 43 
Précis 44 
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Cognitive assessments of children aged 9 from the first CATS study confirms no effect 45 
of treatment for maternal SGTF on IQ<85 and no IQ difference when compared with 46 
children from euthyroid mothers.  47 
48 
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Introduction 49 
Triiodothyronine (T3) and thyroxine (T4) are essential for early brain development, and 50 
maternal thyroid hormones are required by the fetus until its own thyroid starts to 51 
function, which can be as late as 18 weeks gestation. (1-3). Prior to this thyroid 52 
hormones in the fetal brain are solely of maternal origin (4,5). Thyroid dysfunction 53 
occurs in around 2.5% of pregnancies (6) and severe hypothyroidism during the first 54 
two trimesters may result in irreversible neurological deficits, although the effect of 55 
more modest variation in thyroid hormone levels is unclear. Later in pregnancy the 56 
fetus may be better able to compensate for any lack of maternal thyroid hormones but 57 
compensation is likely to be incomplete until the fetal thyroid is fully functional at term. 58 
(7).  59 
Several studies reported that higher levels of maternal thyroid stimulating hormone 60 
(TSH) during pregnancy may be associated with a negative impact on the child’s 61 
intelligence (8-11), but this was not confirmed by others (12,13). Likewise, findings for 62 
low maternal T4 levels are contradictory with some (9,13-17), but not all (10,18-21) 63 
studies providing evidence of lowered intelligence in the children. As well as 64 
intelligence quotient (IQ) and general cognition, further deficits for offspring following 65 
exposure to underactive maternal thyroid function have been identified; including 66 
memory (15,22-25) and motor difficulties (8,9,16,26,27), amongst others.  67 
The Controlled Antenatal Thyroid Screening (CATS) study commenced in 2002 68 
(CATS-I) and was the first randomised controlled trial (RCT) to investigate the effect 69 
of screening and treatment for hypothyroidism during pregnancy on child cognition 70 
(28). Women (n=21,846) were recruited at a median gestation of 12 weeks, 3 days; 71 
(ten UK centres and one in Turin, Italy). Mothers were defined as having suboptimal 72 
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gestational thyroid function (SGTF) if their FT4 was <2.5th percentile and/or TSH 73 
>97.5th percentile as assessed during the CATS study and half were treated with 74 
150µg thyroxine daily. Offspring born to SGTF mothers had their IQ assessed at age 75 
3 years no difference was found between those whose mothers were treated (mean 76 
IQ 99·2) or untreated (100·0) during pregnancy (p=0·40). Similar results were obtained 77 
in a recent study from Casey and colleagues who reported no beneficial effect, on 78 
offspring cognition up to age 5, of treating mothers with subclinical hypothyroidism or 79 
hypothyroxinemia at 16.7 or 17.8 weeks mean gestation respectively (29). The young 80 
age of the children when tested in these large RCTs might explain the reported lack 81 
of treatment effect. IQ evaluations below age 5 may serve as a general indicator of 82 
cognitive function but may not be best suited as a longer term measure of cognitive 83 
function (30). Therefore the primary aim of CATS II was to measure the children’s 84 
cognitive function at age 9 years using a more in-depth battery of tests. Furthermore, 85 
neither of these trials compared the IQs of children from euthyroid mothers with those 86 
of SGTF mothers to elucidate whether there is a deficit requiring treatment. Our 87 
second aim addressed this point by assessing cognitive function in children from 88 
mothers with normal gestational thyroid function (normal-GTF). The dose of thyroxine 89 
used in the CATS study was relatively high and recent reports suggest adverse effects 90 
of cognition from both too much and too little thyroid hormone (31). Consequently we 91 
explored a possible effect of ‘over-treatment’ (defined as maternal FT4 above the 92 
97.5th percentile of the CATS-I UK cohort) on IQ scores. Finally we analysed the 93 
correlation between cognitive assessments undertaken at age 3 and 9 years as this 94 
will be invaluable when designing future studies.   95 
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Methods 96 
Study Design and Population 97 
The original CATS study was previously described in detail (28). Briefly CATS-I 98 
recruited 21,846 women (excluding history of thyroid disease, twin pregnancies, 99 
maternal age <18 years or gestational age >15 weeks and 6 days), predominantly in 100 
the UK, at their first antenatal hospital appointment. Participants were randomized 101 
either to screen (treated) or control (untreated) groups; the former having their thyroid 102 
function tested immediately and the latter after their child was born.  If the mother’s 103 
FT4 was <2.5th percentile and/or TSH >97.5th percentile, they were classified as 104 
having SGTF; percentiles being calculated from the CATS cohort. Women in the 105 
screen group with SGTF were treated with levothyroxine (starting dosage 150µg) for 106 
the remainder of their pregnancies. The primary outcome was children’s IQ at age 3 107 
from the screen and control groups. 108 
CATS-II included only UK participants for logistical reasons (n=16,346). The target 109 
sample size was informed by prior power calculations (see below). All CATS mothers 110 
from the UK SGTF treated and untreated groups (n=609) were invited to participate 111 
by letter. The Welsh Demographics Service and Patient Data Registrar provided 112 
current addresses. Those without SGTF in the control and screen branches of the 113 
RCT, were pooled (UK n=15 737), and named ‘normal-GTF’; a random sample of 114 
4,000 from this group was also invited to participate, again by letter (figure 1). 115 
Cognitive Assessments 116 
CATS-II IQ and additional cognitive assessments were conducted when children were 117 
aged 7·00 to 10·92 years (32); either in the research centre or in their homes. One 118 
psychologist (CH) undertook all of the CATS-II assessments to allow good consistency 119 
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and was unaware of participant group. Ten percent of assessments were double 120 
scored (RP) to ensure accuracy (32). IQ was measured using the Wechsler 121 
Intelligence Scale for Children (WISC) fourth edition UK version which generated a 122 
full-scale IQ (FSIQ) calculated equally from four sub-domains: verbal comprehension 123 
IQ (VCIQ), perceptual reasoning IQ (PRIQ), working memory IQ (WMIQ) and 124 
processing speed IQ (PSIQ). Additional cognitive assessments (8,22) were 125 
administered to some children (those not too tired following WISC administration) 126 
using the Developmental Neuropsychological Assessment (NEPSY) second edition, 127 
details can be found in the supplemental information. These assessments tested long-128 
term memory (memory for designs delayed- MDD, and list memory- LM), working 129 
memory (memory for designs- MD, and narrative memory- NM) and fine motor 130 
coordination (fingertip tapping dominant hand- FTDH, and fingertip tapping non-131 
dominant hand, FTNDH). As the normal-GTF group means for both assessments were 132 
close to the anticipated values (WISC-IV IQ:100, additional NEPSY assessments:10), 133 
the authors conclude there was no selection bias in which children completed all 134 
assessments in CATS-II.  135 
CATS-II was approved by the Wales Research Ethics Committee 2 (reference 136 
10/WSE03/33) and Cardiff & Vale University Health Board. Written and informed 137 
consent was obtained from all mothers both in CATS-II and initially during their 138 
pregnancies; child assent was obtained during the research centre visits. Missing data 139 
were largely due to non-response to invitation. 140 
Sample Size Justification 141 
Samples of 120 participants from the treated (CATS-I screen) and untreated SGTF 142 
(CATS-I control) groups would have 90% power to detect a difference of 6 points in 143 
mean IQ (31) or 80% power with a 5% two-sided significance level to detect a 1.97 144 
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increase in odds of IQ < 85 in untreated SGTF assuming mean IQ to be 100 with a SD 145 
of 15 (32). 240 participants (1.5%) from the normal-GTF group (CATS-I normal thyroid 146 
function in test and screen groups) were required to assess whether maternal SGTF 147 
influenced her child’s IQ. 148 
Analyses 149 
The data were analysed in SPSS version 20 and STATA version 12 in accordance 150 
with the pre-specified statistical plan (32).  151 
The primary analysis assessed the odds of FSIQ <85 in the normal-GTF and the 152 
merged SGTF group; an interaction term for treatment of SGTF was then added, all 153 
using logistic regression. Mean IQ differences and percentages with FSIQ<85 were 154 
also compared between the three groups. Univariate analysis was followed by 155 
multivariate analysis to adjust for key potential covariates in four models: 156 
Model 1; Crude 157 
Model 2; adjusted for child sex 158 
Model 3; adjusted for model 2, and age of mothers at birth of offspring and whether 159 
the child was breastfed. 160 
Model 4; adjusted for model 3, and schooling (Welsh- or English-medium school 161 
attended), place of assessment (home or research centre) and socioeconomic status 162 
(calculated from postcode social deprivation scores obtained from  163 
https://statswales.wales.gov.uk/Catalogue/Community-Safety-and-Social-164 
Inclusion/Welsh-Index-of-Multiple-Deprivation/WIMD-2014 for Wales and  165 
http://apps.opendatacommunities.org/showcase/deprivation for England.  A score of 1 166 
signifies most deprived and 5 least deprived.) 167 
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Step-wise analysis of covariates was performed only for binary outcomes but all six 168 
covariates were included in continuous analyses.  169 
Secondary analyses explored several aspects. We assessed using likelihood ratio 170 
tests whether response to treatment best fitted a proportional or non-propotional 171 
model. Using the normal-GTF to the untreated SGTF data we could investigate 172 
whether maternal TSH influenced FSIQ.  173 
We also compared subdomain-IQs (VCIQ, PRIQ, WMIQ, and PSIQ) in the treated and 174 
untreated SGTF groups to explore the effect of treatment; initially by logistic 175 
regressions for scores <85, then a multivariate analysis of covariance (MANCOVA, 176 
adjusted for the six covariates) for mean scores. The additional cognitive assessments 177 
were also compared by a MANCOVA, and an analysis of covariance (ANCOVA) for 178 
the LM subtest (reduced dataset due to late introduction). 179 
Sensitivity analyses comprised comparison of CATS-I and CATS-II VCIQ, PRIQ and 180 
FSIQs using Pearson correlations. 181 
As exploratory analyses, within the broad term of SGTF, we investigated subclinical 182 
hypothyroidism (FT4 >2·5th and TSH >97·5th percentiles), isolated hypothyroxinaemia 183 
(FT4 <2·5th and TSH <97·5th percentiles), and overt hypothyroidism (FT4 <2·5th and 184 
TSH >97·5th percentiles). These were calculated by MANCOVAs (IQs, additional 185 
cognitive assessments, and LM) to include interactions between the three groups; 186 
normal-GTF, and whether maternal SGTF was treated or not. 187 
Finally, we explored differences between participants taking account of those we 188 
defined as ‘overtreated’ i.e the treated SGTF group whose FT4 values were above the 189 
17.7pmol/L threshold established by the 97.5th percentile at recruitment in the UK 190 
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CATS sample. We compared over-supplementation to child FSIQ <85 first, followed 191 
by analyses for mean scores, all adjusted for the same covariates detailed above. 192 
Supplemental exploratory analyses can be found in the supplemental information: 193 
Subclinical hypothyroidism, isolated hypothyroxinemia and overt hypothyroidism.   194 
Results 195 
Group characteristics 196 
In CATS-I, 16 346 women were UK-based and provided the prospective cohort for 197 
CATS-II. There were 382 treated and 371 untreated for SGTF; of these, 303 treated 198 
and 306 untreated SGTF offspring completed IQ testing at age 3·2 years. No data 199 
were collected from the normal-GTF group. 200 
In CATS-II, IQ assessment occurred in a total of 449 children at a mean age of 9·5 201 
years; 119 treated SGTF, 98 untreated SGTF, and 232 from the normal-GTF group 202 
(figure 1). Smaller groups completed the additional cognitive assessments (please see 203 
supplementary data for explanations); 110 treated SGTF, 85 untreated SGTF, and 204 
215 normal-GTF.  205 
At recruitment into CATS-I, CATS-II mothers from normal-GTF, treated and untreated 206 
SGTF groups had median TSHs of 1.16, 4.09, and 3.57mU/L, respectively and mean 207 
FT4s were 14.12, 11.92, and 11.79pmol/L, respectively (table 1).  The CATS-I and 208 
CATS-II SGTF samples were largely unbiased (statistics presented in supplementary 209 
table 1). 210 
Significant differences between the CATS-II participant groups are detailed in table 1. 211 
As anticipated, maternal FT4 and TSH at recruitment into CATS-I were higher (FT4) 212 
and lower (TSH), in the normal-GTF compared with both SGTF groups. Maternal TSH 213 
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was higher in the treated compared with untreated SGTF CATS-II mothers. Mean 214 
maternal age at consent into CATS-I was higher in the normal-GTF compared to the 215 
treated SGTF group, though only by 0.8 years. Similarly, a difference between the 216 
groups was seen in those from the SGTF groups being more likely to opt for 217 
participation from their home rather than attending the research clinic. The children in 218 
the normal-GTF group were significantly older (by just 4 months) than the SGTF 219 
groups. 220 
Primary analysis 221 
There was no significant difference for odds of FSIQ <85 between the normal-GTF 222 
and merged SGTF groups (fully adjusted OR=1.15 (95% CI 0.52, 2.51) p=0.731). This 223 
non-significant finding was sustained when an interaction term for treatment was 224 
included, although treatment improved FSIQ (untreated fully adjusted OR=1.33 (95% 225 
CI 0.53, 3.34), treatment OR=0.75 (95% CI 0.27, 2.06) p=0.576). Table 2 displays the 226 
FSIQ regression models.  227 
The percentages with IQ<85 were 6.03% in normal-GTF, 7.56% in treated and 11.22% 228 
in untreated SGTF groups (table 3, Chi p for the trend = 0.11). 229 
Secondary analyses 230 
Do data fit a proportional or non-proportional model? 231 
Mean child FSIQs per group were 103.10 (SD 11.68), 101.76 (12.04), and 102.31 232 
(13.27), for the normal-GTF, treated and untreated SGTF groups, respectively (table 233 
3). There was no difference between the mean FSIQ scores of the three participant 234 
groups (p=0.678). There was no significant difference for odds of the normal-GTF 235 
children having higher FSIQs compared to the treated SGTF children (OR=0.99 (95% 236 
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CI 0.38, 2.52) p=0.98); this was due to a mean IQ difference of only 0.79 between the 237 
groups.    238 
Does maternal TSH predict FSIQ? 239 
Analysis of the relationship between FSIQ and thyroid status in normal-GTF and 240 
untreated SGTF revealed no clear association between TSH (B=0.43 (95% CI -0.68, 241 
1.56) p=0.442) and FT4 (B= 0.33 (95% CI -0.25, 0.91) p=0.270) on FSIQ in the fully 242 
adjusted model. 243 
Analysis of women with SGTF by dividing FSIQ score into quintiles did not reveal any 244 
benefit of treatment in the fully adjusted model (p=0.98) with no evidence of a non-245 
proportional effect (p=0.75) (data not shown). 246 
Does treatment for SGTF affect any subdomain? 247 
No differences were found between subdomain-IQ scores <85 (see table 2 for sub-IQ 248 
regression models) or for mean subdomain-IQ scores for VCIQ, PRIQ, WMIQ, and 249 
PSIQ between the groups (p=0.193). The mean scores of the additional cognitive 250 
assessments were also compared, with no difference identified between the three 251 
participant groups (p=0.732, LM p=0.266, table 3).  252 
Sensitivity Analysis 253 
As CATS-II followed the UK sample we analysed the CATS-I UK only cohort (n=609) 254 
and revealed IQ<85 in 14% treated and 17% untreated, the difference was not 255 
significant. Furthermore there was no significant difference in percentage IQ<85 256 
treated versus untreated in the CATS-II subset of CATS-I (n=212). 257 
Pearson correlations to assess how associated the scores were from the WPPSI-III 258 
and the WISC-IV for the treated and untreated SGTF groups found that all scores were 259 
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positively correlated (p<0.0001). Furthermore age 3 IQ predicts 45% of the variation 260 
in age 9 IQ with other variables such as breast feeding contributing only an additional 261 
1%. 262 
Exploratory analyses 263 
Different types of abnormal thyroid function (subclinical hypothyroidism, isolated 264 
hypothyroxinema) were also explored using MANCOVA. No significant differences 265 
were found in the mean IQ scores, IQ<85 or additional assessments between children 266 
of treated and untreated mothers. Similar results were obtained in the offspring of a 267 
small number of women with overt hypothyroidism identified during participation in 268 
CATS, although IQ<85 was apparent in 0% of the treated but 10% of the untreated 269 
groups. These analyses are presented in supplementary table 2.  270 
 271 
Over-supplementation 272 
Finally, we explored differences between participants, taking account of those in the 273 
treated SGTF group with raised FT4 values (20 weeks mean FT4 16.19 (2.83), TSH 274 
median 0.33 (0.08-0.99); 30 weeks mean FT4 15.56 (2.50), median TSH 0.27 (0.03-275 
0.84). The threshold for high FT4 was established by the 97·5th percentile recruitment 276 
in the UK CATS sample (17.7pmol/L); one-third of the treated SGTF had FT4 277 
>17.7pmol/L. 278 
We compared over-supplementation to child FSIQ <85 first, followed by analyses for 279 
mean scores, all adjusted for the same covariates detailed above. There was no 280 
significant effect on child’s IQ<85 and no difference between mean IQ scores of the 281 
groups or additional cognitive assessments, including the LM subtest (p=0.875, 282 
p=0.765, p=0.951, respectively), data not shown.  283 
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Of note, we observed no detrimental effect of over-supplementation on IQ<85 in 284 
children of such women in CATS-I for whom we had information on FT4 levels after 285 
therapy was initiated (UK cohort, n=609). 286 
Discussion 287 
We revisited the effects of treatment for SGTF on cognition in the CATS children at an 288 
average age of 9.5 years. Our results confirm those of CATS-I, in that we saw no 289 
significant differences in FSIQ<85 or mean IQ scores in the children of treated and 290 
untreated women. Our results also confirm those of Casey and colleagues who 291 
reported no beneficial effect, on offspring cognition up to age 5, of treating mothers 292 
with subclinical hypothyroidism or hypothyroxinemia at 16.7 or 17.8 weeks mean 293 
gestation respectively (29). Of interest Haddow et al (8) reported that mean FSIQ 294 
scores and FSIQ scores <85 were not significantly different comparing children born 295 
to mothers who were treated or not (p=0.20 and p=0.90, respectively), although the 296 
study was retrospective and the treatment groups were small. In contrast to our 297 
findings however the study by Haddow et al showed that the IQ of children born to 298 
untreated mothers was significantly lower than those of control children. 299 
 300 
One criticism of CATS-I was that cognitive assessments were conducted in children 301 
at too young an age for differences to be evident Our current findings indicate that this 302 
may not be the case as we found that IQ scores at age 3 and 9 were strongly correlated 303 
in the two CATS studies with FSIQ at age 3 predicting 45% of the variability in FSIQ 304 
at age 9 and with other factors contributing very little.  305 
 306 
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The design of the CATS-I study has also been questioned in relation to the timing of 307 
initiation of levothyroxine therapy. The fetus relies wholly on maternal thyroxine 308 
delivery up until about 14-18 weeks gestation when its own thyroid gland becomes 309 
functional (7). Fetal brain development begins immediately after conception and 310 
therefore treatment initiated at 12-13 weeks may have missed the early critical phase 311 
of brain development. The CATS study participants were recruited during their first 312 
scheduled visit to the antenatal clinic which generally fell towards the end of the first 313 
trimester (median of 12 weeks and 3 days). (33) Similarly, thyroxine supplementation 314 
in the study by Casey et al  (29) was started even later and thus future trials would 315 
benefit from recruiting women at a much earlier stage of pregnancy in order to 316 
overcome these limitations.  317 
A further consideration in the CATS study design is that the starting dose of 318 
levothyroxine administered may have been too high and therefore adverse outcomes 319 
in women who were over-treated may have masked any benefits of treatment. The 320 
CATS-I study was the first RCT to investigate the effects of treatment for SGTF in 321 
pregnancy and hence there were no previous studies for guidance. Furthermore, there 322 
is no universal consensus on thyroxine supplementation dose even for the treatment 323 
of women with overt hypothyroidism who become pregnant. Of note, guidelines for the 324 
management of thyroid function during pregnancy recommend assay of TSH alone 325 
and indeed treatment in CATS-I was monitored and adjusted based on TSH levels. As 326 
a result, approximately one third of the treated mothers achieved a high FT4 which 327 
was accompanied by a switch from a positive correlation between FT4 and age 9 328 
cognition at recruitment to a negative correlation after treatment (supplemental 329 
information). However, in contrast to a study illustrating a bi-phasic effect of FT4 on 330 
cognition, with children of women with both low and high thyroxine levels displaying 331 
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lower IQs and smaller grey matter and cortex volumes (35) (31), we observed no 332 
significant difference in the proportion of IQ<85 at age 9 in children of over-treated 333 
mothers compared with the rest. Furthermore we did not find any detrimental effect on 334 
IQ<85 in children of such women when we analysed the age 3 cognition data in CATS-335 
I (UK only cohort).  336 
CATS-II included children from normal-GTF women and found no difference in IQ 337 
measures between these and children from SGTF mothers, whether treated or not. 338 
This confirmed previous studies reporting no effect of low thyroid function on offspring 339 
intelligence or cognition (10,12,13,18-21) and may to some extent explain the absence 340 
of treatment benefits observed in the trial.  However our results contradict many animal 341 
studies possibly because the thyroid abnormalities in the CATS mothers are mild when 342 
compared with models induced e.g. by thyroidectomy.  The lack of agreement on the 343 
effects of FT4 on cognition in observational studies is the result of varying definitions 344 
of SGTF, the lack of universal pregnancy-specific reference ranges for thyroid function 345 
tests and the application of various tools to measure cognition in children across the 346 
age spectrum. Hence it is not surprising that the benefits of universal screening during 347 
pregnancy on cognition remain hotly debated although other adverse pregnancy 348 
outcomes have been well-reported (such as pre-eclampsia, miscarriage, and preterm 349 
birth) (34-36).  350 
In our protocol paper (32) one of the secondary analyses planned to investigate 351 
whether the combination of low maternal FT4 during pregnancy and the presence of 352 
an adverse deiodinase 2 (D2) genotype in her child would impact cognition. The 353 
hypothesis followed reports that Thr92Ala reduced conversion of thyroxine to tri-354 
iodothyronine (37).  We genotyped 426 CATS children finding 73 alanine 355 
homozygotes;  when a mother had low FT4 during pregnancy and the child had the 356 
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homozygous alanine D2 genotype, treatment appeared to reduce the odds of 357 
FSIQ<85 (reduced OR from 5.72 to 1.85), though this was non-significant and included 358 
only a small number of the participants (data not shown).  359 
Our study has some limitations although throughout all analyses adjustments were 360 
made to control for extraneous effects. 1. The CATS-II power calculation was based 361 
on an IQ difference of 6 points, as found by Haddow et al in offspring of women with 362 
overt hypothyroidism. We studied women with less severe thyroid dysfunction and 363 
thus the study may have been underpowered to detect more subtle cognitive variation. 364 
2. This was exacerbated by the recruitment challenges we faced from the outset, with 365 
the main problem due to participants having re-located since participating in CATS-I 366 
and not responding to invitation. As the study developed, the recruitment process 367 
evolved and rates improved but extending the data collection period would have taken 368 
the children closer to puberty and its complications. 3. There were some differences 369 
noted between the three groups raising the possibility of bias. However, significantly 370 
older normal-GTF children than those from the SGTF groups should not have affected 371 
the results since both assessment tools used have scores age-corrected in three 372 
month intervals. Similarly differences in maternal age at recruitment and place of child 373 
assessment were both covariates controlled for in the analyses. 374 
In conclusion, results obtained in the current follow-up study have  shown no effect of 375 
thyroxine supplementation in women with SGTF on child IQ at age 9. These findings 376 
support those of the original CATS-I study and a recent large RCT.  Our data are 377 
consistent with the lack of treatment effect being due to the similar proportion of IQ<85 378 
in children of normal-GTF and SGTF mothers rather than the age of cognitive 379 
assessment or the relatively high dose of thyroxine supplementation. However, future 380 
large randomised trials, with thyroxine interventions at a much earlier stage of 381 
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pregnancy (or pre-conception), may still be warranted, since the benefits of treatment 382 
may not be fully realised unless treatment is commenced early.  383 
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 500 
Legends to Figures and Tables 501 
Table 1: Characteristics of the cohort. Data are expressed as median (Interquartile 502 
range, IQR), mean (standard deviation, SD) or the Number (N) of participants 503 
(percentage, %). Socioeconomic status is based on a social deprivation score with 1 504 
being the most deprived. Child’s language describes whether the child speaks English 505 
(Engl) both at home and in school, Welsh in both locations, a combination of English 506 
and Welsh or an additional language. GTF=gestational thyroid function; 507 
SGTF=suboptimal gestational thyroid function; CATS=controlled antenatal thyroid 508 
screening. 509 
Table 2: Logistic regressions for odds of IQ below 85.  Data are expressed as 510 
Odds Ratios (OR) with 95% confidence intervals (95% CI). SGTF=suboptimal 511 
gestational thyroid function. FSIQ=full scale intelligence quotient. VCIQ=verbal 512 
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comprehension intelligence quotient. PRIQ=perceptual reasoning intelligence 513 
quotient. WMIQ=working memory intelligence quotient. PSIQ=processing speed 514 
intelligence quotient. Model 1=unadjusted. Model 2=adjusted for child gender. Model 515 
3=adjusted for model 2 and whether the mother breastfed over one month, and mother 516 
age at time of study consent during pregnancy. Model 4=adjusted for model 3 and 517 
where the child was assessed, child’s language spoken at school and home, and 518 
social deprivation score.  519 
Table 3: Mean scores for IQs. Data expressed as means (standard deviations) of 520 
group, or the Number (N) of participants (percentage, %) having IQ<85. 521 
GTF=gestational thyroid function; SGTF=suboptimal gestational thyroid function; 522 
WISC=Wechsler intelligence scale for children fourth edition UK; VCIQ=verbal 523 
comprehension intelligence quotient, PRIQ=perceptual reasoning intelligence 524 
quotient; WMIS=working memory intelligence quotient; PSIQ=processing speed 525 
intelligence quotient; FSIQ=full scale intelligence quotient; NEPSY=developmental 526 
neuropsychological assessment second edition; MD=memory for designs; 527 
MDD=memory for designs delayed; FTDH=fingertip tapping dominant hand; 528 
FTNDH=fingertip tapping non-dominant hand; NM=narrative memory; LM=list 529 
memory. *reduced dataset 530 
Figure 1: Flow-chart of recruitment to the Controlled Antenatal Thyroid 531 
Screening (CATS) Study Illustrates initial recruitment for CATS-I, when child IQ was 532 
assessed at 3 years of age and the follow-up study CATS-II, in which child IQ was 533 
assessed at 9 years of age. 534 
  535 
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TABLE 1:  536 
 Groups 
Characteristics  Normal-GTF 
 
N=232 
Treated SGTF 
 
N=119 
Untreated 
SGTF 
N=98 
Normal-GTF 
vs. Treated 
SGTF (P) 
Normal-GTF vs. 
Untreated 
SGTF (P) 
Treated SGTF 
vs Untreated 
SGTF (P) 
Thyrotropin at CATS-I 
consent (mlU/L)  
1.16  
(0.66-1.83) 
4.09  
(1.79-5.09) 
3.57  
(1.18-4.49) 
   0.001    0.001    0.007 
Thyroxine at CATS-I 
consent (pmol/L) 
14.12 (1.76) 11.92 (1.93) 11.79 (1.88)    0.001  
 
   0.001  
 
   1.000 
Maternal age at CATS-I 
consent  (years) 
31.85 (5.16) 30.26 (5.08) 31.05 (4.88)    0.018     0.578    0.767 
Social deprivation/Socio-
economic status   
    1 
     2 
4.00 (3-5) 
(mean 3.71) 
26 (11%) 
27 (11%) 
4.00 (3-5) 
(mean 3.78) 
15 (13%) 
12 (10%) 
4.00 (2-5) 
(mean 3.37) 
16 (16%) 
14 (14%) 
   0.807    0.359    0.161 
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     3 
     4 
     5   
36 (15%) 
43 (18%) 
100 (43%) 
15 (13%) 
19 (16%) 
58 (49%) 
17 (17%) 
20 (20%) 
31 (32%) 
Child breastfed over one 
month N (%) 
150 (65%) 72 (60%) 56 (57%) 0.445 0.198 0.616 
Child characteristics 
Male children N (%) 177 (50%) 65 (55%) 49 (50%) 0.457 0.943 0.497 
Child age at participation 9.83  
(9.00-10.33) 
9.58  
(9.08-9.94) 
9.50  
(9.00- 9.94) 
0.001  0.024  0.710 
Where child was 
assessed 
     Home 
     Research centre 
 
 
120 (52%) 
112 (48%) 
 
 
92 (77%) 
27 (23%) 
 
 
79 (81%) 
19 (19%) 
0.001 0.001 0.554 
Child’s language 
     English school/home  
Welsh school/Engl home 
 
180 (78%) 
42 (18%) 
 
95 (80%) 
20 (17%) 
 
85 (87%) 
11 (11%) 
0.950 0.364 0.541 
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     Welsh school/home 
Engl school/other home 
Welsh school/other home 
7 (3%) 
2 (1%) 
1 (1%) 
 
3 (2%) 
1 (1%) 
0 
 
1 (1%) 
1 (1%) 
0 
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Table 2: 538 
IQs MODELS Merged SGTF to 
Normal-GTF OR 
(95% CI) 
P 
Interaction 
OR Untreated 
(95% CI) 
OR treatment 
(95% CI) 
P 
treatment 
interaction 
FSIQ 1 1·58 (0·78, 3·21) 0·206 1·97 (0·86, 4·50) 0·65 (0·26, 1·63) 0·355 
2 1·57 (0·77, 3·19) 0·217 1·98 (0·86, 4·55) 0·63 (0·25, 1·59) 0·325 
3 1·38 (0·66, 2·86) 0·389 1·77 (0·75, 4·16) 0·61 (0·23, 1·58) 0·308 
4 1·15 (0·52, 2·51) 0·731 1·33 (0·53, 3·34) 0·75 (0·27, 2·06) 0·576 
VCIQ 1 1·08 (0·57, 2·03) 0·820 0·89 (0·38, 2·09) 1·38 (0·55, 3·48) 0·491 
2 1·07 (0·57, 2·02) 0·833 0·89 (0·38, 2·09) 1·36 (0·54, 3·44) 0·506 
3 0·99 (0·52, 1·88) 0·968 0·82 (0·34, 1·93) 1·38 (0·54, 3·53) 0·491 
4 0·93 (0·47, 1·83) 0·834 0·70 (0·29, 1·73) 1·62 (0·62, 4·20) 0·317 
PRIQ 1 1·82 (0·84, 3·94) 0·130 2·54 (1·06, 6·07) 0·49 (0·18, 1·33) 0·156 
2 1·82 (0·84, 3·94) 0·131 2·54 (1·06, 6·07) 0·49 (0·18, 1·33) 0·156 
3 1·60 (0·73, 3·53) 0·238 2·31 (0·95, 5·62) 0·46 (0·17, 1·28) 0·132 
4 1·35 (0·59, 3·09) 0·482 1·78 (0·69, 4·56) 0·56 (0·19, 1·58) 0·268 
26 
 
WMIQ 1 1·48 (0·78, 2·81) 0·232 1·35 (0·60, 3·04) 1·17 (0·50, 2·77) 0·715 
2 1·47 (0·77, 2·79) 0·241 1·35 (0·60, 3·05) 1·15 (0·49, 2·73) 0·742 
3 1·33 (0·69, 2·57) 0·393 1·21 (0·53, 2·78) 1·18 (0·49, 2·84) 0·713 
4 1·26 (0·63, 2·53) 0·513 1·04 (0·43, 2·50) 1·42 (0·57, 3·52) 0·449 
PSIQ 1 0·79 (0·36, 1·71) 0·550 0·88 (0·33, 2·32) 0·81 (0·25, 2·61) 0·729 
2 0·78 (0·36, 1·69) 0·524 0·88 (0·33, 2·33) 0·79 (0·24, 2·53) 0·688 
3 0·75 (0·34, 1·63) 0·463 0·85 (0·32, 2·27) 0·77 (0·24, 2·49) 0·664 
4 0·75 (0·33, 1·68) 0·482 0·82 (0·20, 2·24) 0·85 (0·26, 2·77) 0·783 
 539 
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Table 3: 541 
 Groups 
Cognitive 
assessment 
Normal-GTF 
N=232 
Merged SGTF 
N=217 
Treated SGTF 
N=119 
Untreated SGTF 
N=98 
WISC     
VCIQ 
<85 
99·81 (11·26) 
28 (12%) 
98·60 (11·42) 
30 (14%) 
97·56 (9·95) 
19 (16%) 
99·86 (12·93) 
11 (11%) 
PRIQ 
 
<85 
105·37 (12·30) 
11 (5%) 
104·55 (12·87) 
18 (8%) 
104·49 (12·26) 
7 (6%) 
104·63  
(13·64) 
11 (11%) 
WMIQ 
<85 
99·91 (11·24) 
18 (8%) 
99·81 (12·72) 
24 (11%) 
99·73 (13·28) 
14 (12%) 
99·90 (12·07) 
10 (10%) 
PSIQ 
 
<85 
103·66 (12·75) 
22 (9%) 
102·39 (12·73) 
18 (8%) 
103·16 (12·71) 
8 (7%) 
101·45 (12·75) 
10 (10%) 
FSIQ 
 
<85 
103·10 (11·68) 
15 (6%) 
102·01 (12·59) 
21 (10%) 
101·76 (12·04) 
10 (8%) 
102·31  
(13·28) 
11 (11%) 
NEPSY N=215 N=195 N=110 N=85 
     MD 10·36 (2·92) 9.69 (3.13) 9.63 (3.27) 9.76 (2.96) 
     MDD 10·34 (2·65) 9·86 (2·84) 9·77 (2·79) 9·98 (2·92) 
     FTDH 12·24 (1·60) 11·94 (1·45) 11·90 (1·41) 12·01 (1·52) 
     FTNDH 12·51 (1·37) 12·24 (1·41) 12·21 (1·39) 12·31 (1·46) 
     NM 11·56 (2·76) 11·06 (2·76) 11·02 (2·78) 11·12 (2·74) 
28 
 
 N=170 N=146 N=78 N=68 
     LM* 10·93 (2·84) 10·62 (2·86)) 10·63 (3·13) 10·60 (2·54) 
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Figure 1  
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